Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology... Show more
LPCN is expected to report earnings to fall 12.96% to -46 cents per share on August 06
Q2'26
Est.
$-0.47
Q1'26
Missed
by $0.07
Q1'23
Missed
by $0.01
Q4'22
Missed
by $0.31
Q3'22
Missed
by $0.48
The last earnings report on May 07 showed earnings per share of -54 cents, missing the estimate of -46 cents. With 90.28K shares outstanding, the current market capitalization sits at 16.24M.